Skip to main content

Table 1 Characteristics of study subjects before and after treatment

From: Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study

  Control (n = 10) Acarbose (n = 10) Nateglinide (n = 10)
  Baseline 12 weeks Baseline 12 weeks Baseline 12 weeks
Age (years) 68.0 ± 7.7   67.6 ± 6.2   67.8+/-8.6  
Male gender (%) 5 (50)   7 (70)   7 (70)  
BMI (kg/m2) 26.8 ± 3.2 26.1 ± 3.4 25.8 ± 2.5 25.3 ± 7.4 25.8 ± 3.3 25.5 ± 2.9
Total cholesterol (mg/dl) 213.2 ± 15.9 210.2 ± 23.2 201.8 ± 25.4 205.7 ± 38.1 206.0 ± 25.4 211.1 ± 29.6
Triglyceride (mg/dl) 132.4 ± 13.1 127.7 ± 17.1 116.1 ± 20.8 125.5 ± 34.7 121.7 ± 19.3 121.6 ± 22.3
HDL cholesterol (mg/dl) 53.8 ± 11.0 53.7 ± 9.5 56.2 ± 11.0 52.7 ± 14.4 54.4 ± 12.5 57.4 ± 13.2
LDL cholesterol (mg/dl) 135.0 ± 48.8 143.9 ± 52.7 141.6 ± 69.3 137.4 ± 77.3 149.4 ± 76.0 121.6 ± 22.3
HbA1c (%) 5.8 ± 0.6 5.6 ± 0.5 6.0 ± 0.3 5.9 ± 0.4 6.1 ± 0.6 5.8 ± 0.4
Fasting glucose (mg/dl) 110.7 ± 15.0 109.3 ± 12.0 109.6 ± 17.5 108.8 ± 15.7 119.6 ± 17.5 110.4 ± 11.1
Fasting insulin (μU/ml) 7.5 ± 2.9 7.2 ± 2.8 9.6 ± 5.6 10.6 ± 6.8 6.6 ± 4.1 6.5 ± 2.7
HOMA-IR 2.0 ± 0.7 1.9 ± 1.8 2.6 ± 1.6 2.8 ± 1.9 2.0 ± 1.6 1.8 ± 0.7
Systolic BP (mmHg) 143.5 ± 28.5 145.5 ± 38.2 141.1 ± 26.1 142.6 ± 19.1 141.3 ± 28.5 143.8 ± 23.5
Diastolic BP (mmHg) 89.1 ± 19.2 89.3 ± 11.9 88.1 ± 23.1 83.1 ± 38.9 88.3 ± 11.9 89.1 ± 23.8
Heart rate (beats/min) 68.8 ± 9.8 68.8 ± 8.9 69.2 ± 11.1 62.9 ± 11.2 68.2 ± 8.9 68.9 ± 8.2
  1. Data are shown as mean ± SD. BMI, body mass index; HDL, High-density lipoprotein; LDL, Low-density lipoprotein; HbA1c, glycohemoglobin A1c; HOMA-IR, insulin resistance by homeostasis model assessment; BP, blood pressure.